A citation-based method for searching scientific literature


List of co-cited articles
469 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
332
55

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Juan P Frías, Melanie J Davies, Julio Rosenstock, Federico C Pérez Manghi, Laura Fernández Landó, Brandon K Bergman, Bing Liu, Xuewei Cui, Katelyn Brown. N Engl J Med 2021
141
55

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Julio Rosenstock, Carol Wysham, Juan P Frías, Shizuka Kaneko, Clare J Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Chrisanthi A Karanikas, Vivian T Thieu. Lancet 2021
93
51

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
195
48

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar, Juan P Frias, Laura Fernández Landó, Katelyn Brown, Ross Bray, Ángel Rodríguez. Lancet 2021
58
40


Once-Weekly Semaglutide in Adults with Overweight or Obesity.
John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden,[...]. N Engl J Med 2021
388
33

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Stefano Del Prato, Steven E Kahn, Imre Pavo, Govinda J Weerakkody, Zhengyu Yang, John Doupis, Diego Aizenberg, Alan G Wynne, Jeffrey S Riesmeyer, Robert J Heine,[...]. Lancet 2021
43
32

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Melanie Davies, Louise Færch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden,[...]. Lancet 2021
123
28

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Francis S Willard, Jonathan D Douros, Maria Bn Gabe, Aaron D Showalter, David B Wainscott, Todd M Suter, Megan E Capozzi, Wijnand Jc van der Velden, Cynthia Stutsman, Guemalli R Cardona,[...]. JCI Insight 2020
65
26

How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J Samms, Matthew P Coghlan, Kyle W Sloop. Trends Endocrinol Metab 2020
57
26

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
326
24


Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Thomas A Wadden, Timothy S Bailey, Liana K Billings, Melanie Davies, Juan P Frias, Anna Koroleva, Ildiko Lingvay, Patrick M O'Neil, Domenica M Rubino, Dorthe Skovgaard,[...]. JAMA 2021
126
22

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Domenica Rubino, Niclas Abrahamsson, Melanie Davies, Dan Hesse, Frank L Greenway, Camilla Jensen, Ildiko Lingvay, Ofri Mosenzon, Julio Rosenstock, Miguel A Rubio,[...]. JAMA 2021
112
22

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Melissa K Thomas, Amir Nikooienejad, Ross Bray, Xuewei Cui, Jonathan Wilson, Kevin Duffin, Zvonko Milicevic, Axel Haupt, Deborah A Robins. J Clin Endocrinol Metab 2021
46
22


Incretin hormones: Their role in health and disease.
Michael A Nauck, Juris J Meier. Diabetes Obes Metab 2018
251
20

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
20


Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan,[...]. Cell Metab 2019
86
20

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
20

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
161
20

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
17

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
147
17


Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Mark L Hartman, Arun J Sanyal, Rohit Loomba, Jonathan M Wilson, Amir Nikooienejad, Ross Bray, Chrisanthi A Karanikas, Kevin L Duffin, Deborah A Robins, Axel Haupt. Diabetes Care 2020
80
15

Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
404
15

The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins, William C Roell, Jeffrey S Riesmeyer, Axel Haupt, Kevin L Duffin, Marja-Riitta Taskinen, Giacomo Ruotolo. Diabetes Obes Metab 2020
27
25

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
844
15

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier. Mol Metab 2021
139
15

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Robert F Kushner, Salvatore Calanna, Melanie Davies, Dror Dicker, W Timothy Garvey, Bryan Goldman, Ildiko Lingvay, Mette Thomsen, Thomas A Wadden, Sean Wharton,[...]. Obesity (Silver Spring) 2020
69
15

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
Ricardo J Samms, Michael E Christe, Kyla Al Collins, Valentina Pirro, Brian A Droz, Adrienne K Holland, Jessica L Friedrich, Samantha Wojnicki, Debra L Konkol, Richard Cosgrove,[...]. J Clin Invest 2021
27
25

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.
Jens Juul Holst, Mette Marie Rosenkilde. J Clin Endocrinol Metab 2020
44
13

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
830
13

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
353
13


Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
907
13


Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.
Michael E J Lean, Wilma S Leslie, Alison C Barnes, Naomi Brosnahan, George Thom, Louise McCombie, Carl Peters, Sviatlana Zhyzhneuskaya, Ahmad Al-Mrabeh, Kieren G Hollingsworth,[...]. Lancet Diabetes Endocrinol 2019
261
13


The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger,[...]. Cell Metab 2021
47
13

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
81
13


Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
938
13


Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
983
11

GIP and GLP-1, the two incretin hormones: Similarities and differences.
Yutaka Seino, Mitsuo Fukushima, Daisuke Yabe. J Diabetes Investig 2010
322
11

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
11

Pharmacotherapy of obesity: Available medications and drugs under investigation.
Eleni Pilitsi, Olivia M Farr, Stergios A Polyzos, Nikolaos Perakakis, Eric Nolen-Doerr, Aimilia-Eirini Papathanasiou, Christos S Mantzoros. Metabolism 2019
92
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.